Recent Report on Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
To access full report with TOC, please visit Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 43, 45, 1, 3, 54, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 6, 8 and 7 molecules, respectively.Chronic Lymphocytic Leukemia (CLL).
Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG AbbVie Inc Acetylon Pharmaceuticals Inc Aeglea BioTherapeutics Inc Altor BioScience Corp Amgen Inc Aprea AB Aptevo Therapeutics Inc Arno Therapeutics Inc ArQule Inc Astellas Pharma Inc Astex Pharmaceuticals Inc Baliopharm AG Bayer AG BeiGene Ltd Bellicum Pharmaceuticals Inc Biogen Inc Bionomics Ltd Bionovis SA Biothera Pharmaceutical Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corp Cellectis SA Cellular Biomedicine Group Inc Coherus BioSciences Inc CrystalGenomics Inc Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd Eli Lilly and Company F. Hoffmann-La Roche Ltd GeneaMed Ltd Genentech Inc Genor BioPharma Co Ltd Gilead Sciences Inc Grupo Ferrer Internacional SA Hutchison MediPharma Ltd Hybrigenics SA Igenica Biotherapeutics Inc Immatics Biotechnologies GmbH ImmunoGen Inc Immunomedics Inc Incyte Corp Inflection Biosciences Ltd Innate Pharma SA Innovent Biologics Inc Johnson & Johnson Juno Therapeutics Inc Kancera AB Karyopharm Therapeutics Inc Kite Pharma Inc Les Laboratoires Servier SAS LFB SA Lymphocyte Activation Technologies SA Medicenna Therapeutics Inc MENTRIK Biotech LLC Merck & Co Inc Merck KGaA Mesoblast Ltd Millennium Pharmaceuticals Inc MorphoSys AG NantKwest Inc Nordic Nanovector ASA Novartis AG Oncternal Therapeutics, Inc. Ono Pharmaceutical Co Ltd Panacea Biotec Ltd PEP-Therapy SAS Pfizer Inc Pharmacyclics Inc PIQUR Therapeutics AG Portola Pharmaceuticals Inc Redx Pharma Plc Respiratorius AB Revitope Oncology, Inc. Rhizen Pharmaceuticals SA Sandoz International GmbH Sanofi Selvita SA Simcere Pharmaceutical Group Sorrento Therapeutics Inc Supratek Pharma Inc Takeda Pharmaceutical Company Ltd Targazyme Inc TG Therapeutics Inc The International Biotechnology Center (IBC) Generium Theravectys SA Tolero Pharmaceuticals Inc TRACON Pharmaceuticals Inc Tragara Pharmaceuticals Inc Trillium Therapeutics Inc United BioPharma, Inc. Unum Therapeutics Inc Verastem Inc VioQuest Pharmaceuticals Inc Viralytics Ltd Xencor Inc ZIOPHARM Oncology Inc Zymeworks Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 20:28
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home